Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus dual antiplatelet therapy after PFO/ASD closure
NL-OMON57764Phase 2Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban, aspirin, clopidogrel in patent foramen ovale (PFO), atrial septal defect (ASD), sponsored by St. Antonius Ziekenhuis. Started Apr 2022; status: recruiting.
02
Drugs
rivaroxabanaspirinclopidogrel
03
Conditions
patent foramen ovale (PFO)atrial septal defect (ASD)
Beyond the preview
Go deeper on NL-OMON57764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57764.